Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price Neurocrine Biosciences exemplifies GARP investing, blending strong earnings growth, solid profitability, and a reasonable stock price within its sector.
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup Neurocrine Biosciences (NBIX) combines strong growth, high profitability, and a positive technical breakout setup in the neuroscience sector.
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.
High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration Discover NBIX, a top momentum stock with accelerating EPS growth of 64.5%, rising profit margins, and a perfect technical rating for a potential breakout.
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
